Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Risk factors

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

From 2016 to 2022, Alzheimer’s disease mortality significantly increased among Black individuals (AAPC = 8.3%, 95% CI [2.6 to 16.0]; p < 0.05) and declined among White individuals (AAPC = −2.9%, 95% CI [−12.3 to 7.6] p < 0.05). Gender-specific analyses showed slight, non-significant increases among both males and females. County-level disparities were evident: counties such as Sharkey experienced increases exceeding 10%, while Humphreys counties showed declines. Racial disparities in AD mortality were more pronounced than gender differences. This study reveals widening racial and geographic disparities in Alzheimer’s disease mortality across the Mississippi Delta. The statistically significant increase among Black seniors highlights structural inequities in early diagnosis, access to culturally appropriate care, and chronic disease management. These findings support the need for targeted public health interventions, such as the expansion of rural memory clinics, culturally competent outreach, and Medicaid-supported long-term care. Strengthening surveillance systems like MSTAHRS is critical to tracking disparities and advancing equity in dementia-related mortality.

What this study adds

Evidence grade: Low

This study found that Alzheimer's disease mortality increased significantly among Black individuals and declined among White individuals in the Mississippi Delta from 2016 to 2022. Reported effect size: 8.3%; 2.9%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gavari, N., Adjei, J., Barner, Y. M., Mitra, A. K., Moore, S., & Jones, E. A. (2025). Trends in Alzheimer’s Disease Mortality in the Mississippi Delta, 2016–2022. Journal of dementia and Alzheimer's disease. https://doi.org/10.3390/jdad2040044

Vancouver

Gavari N, Adjei J, Barner YM, Mitra AK, Moore S, Jones EA. Trends in Alzheimer’s Disease Mortality in the Mississippi Delta, 2016–2022. Journal of dementia and Alzheimer's disease. 2025. doi:10.3390/jdad2040044.

BibTeX

@article{gavari2025-65bf5c9b,
  author  = {Gavari, Nafiseh and Adjei, Jazmin and Barner, Yalanda M. and Mitra, Amal Krishna and Moore, Sheila and Jones, Elizabeth A.},
  title   = {{Trends in Alzheimer’s Disease Mortality in the Mississippi Delta, 2016–2022}},
  journal = {Journal of dementia and Alzheimer's disease},
  year    = {2025},
  doi     = {10.3390/jdad2040044},
  url     = {https://doi.org/10.3390/jdad2040044}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that Alzheimer's disease mortality increased significantly among Black individuals and declined among White individuals in the Mississippi Delta from 2016 to 2022. It describes disparities in death rates and does not test any treatment, cure, or prevention.

Study details

How this study scored 30/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 30 of 100.30 of 100 points earned70 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of dementia and Alzheimer's disease)
Journal's citation record 0 / 4 Journal of dementia and Alzheimer's disease: journal h-index 7 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Elizabeth A. Jones: h-index 34 (OpenAlex, whole career)
Institution's track record 0 / 3 Texas Tech University: institution h-index 686 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 30 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk factors from nearby years

Also in Risk factors

395 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.

Similar studies

More on Risk factors

See all studies in Risk factors →